Deadline: October 15, 2025
The MAHA MedTech Mission aims to advance equitable access to high-quality, affordable, and innovative medical technologies to improve healthcare.
The focus areas for this mission are to support development and commercialization of indigenous, high-quality, affordable, and innovative medical technologies with established proof-of-concept, and to foster indigenous development of high priority, high-cost, imported medical technologies to promote self-reliance and adaptation for the Indian population.
This mission will support the development and commercialization of high-quality, affordable, and innovative medical technologies. It also seeks to strengthen the indigenous development of imported medical technologies that are high priority and high cost, ensuring they are adapted for low-resource settings in India. Another important aspect of the mission includes enhancing existing infrastructure for medical device development at government-supported institutions and centers of excellence, with special funds allocated for technologies ready for production.
The mission will span five years, with a total funding outlay of 750 crores. Each project may receive funding between 5 crores to 25 crores, with exceptional cases receiving up to 50 crores. Funding is milestone-linked and projects can be divided into sub-projects focused on stages such as bioengineering, preclinical and clinical development, and industry/startup support, coordinated with appropriate funding sources including ANRF, ICMR, and Gates Foundation. Participation is open to industry, MSMEs, and startups, subject to terms and conditions decided by a Technical Advisory Group.
The mission targets innovative medical devices and in vitro diagnostics, including cutting-edge technologies like imaging, radiotherapy equipment, robotics, minimally invasive technologies, implants, and AI/ML-enabled platforms aligned with National Health Missions and ICMR priority list. Therapeutics and vaccines are not the immediate focus of this call.
Eligibility requirements include technologies with established proof-of-concept at TRL-3 or above, indigenous technologies targeting replacement of high-cost imported health technologies with significant cost reduction, and strong collaboration between academia, biomedical and engineering institutes, hospitals, and industry partners.
The expected outcomes include the development of affordable MedTech products meeting international regulatory standards and the establishment of a collaborative culture between academia, engineering, medical sectors, and industry through public-private partnerships.
Applications for the concept note will be accepted until October 15, 2025. The process involves submission through the ANRF online portal, evaluation, and selection for full proposal submission. Subsequent stages include application review and grant release preparations, with timelines extending into early 2026.
For more information, visit ANRF.
